Neurogene (NASDAQ:NGNE – Get Free Report) and CytoMed Therapeutics (NASDAQ:GDTC – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, earnings and valuation.
Institutional and Insider Ownership
52.4% of Neurogene shares are held by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are held by institutional investors. 11.7% of Neurogene shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Ratings
This is a breakdown of recent recommendations for Neurogene and CytoMed Therapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Neurogene | 1 | 0 | 3 | 2 | 3.00 |
| CytoMed Therapeutics | 1 | 0 | 0 | 0 | 1.00 |
Risk and Volatility
Neurogene has a beta of 1.69, indicating that its stock price is 69% more volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.05, indicating that its stock price is 105% less volatile than the S&P 500.
Valuation & Earnings
This table compares Neurogene and CytoMed Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Neurogene | $930,000.00 | 535.67 | -$90.35 million | ($4.55) | -6.93 |
| CytoMed Therapeutics | $250,000.00 | 52.53 | -$3.10 million | N/A | N/A |
CytoMed Therapeutics has lower revenue, but higher earnings than Neurogene.
Profitability
This table compares Neurogene and CytoMed Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Neurogene | N/A | -37.88% | -34.70% |
| CytoMed Therapeutics | N/A | N/A | N/A |
Summary
Neurogene beats CytoMed Therapeutics on 9 of the 12 factors compared between the two stocks.
About Neurogene
Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.
About CytoMed Therapeutics
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers and degenerative diseases in Malaysia and Singapore. Its lead product candidate is CTM-N2D, an expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor, which is in Phase I clinical trials comprising to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, a pluripotent stem cell-derived gamma delta natural killer T cells platform for cancer treatment; CTM-GDT, a product candidate that consists of expanded allogeneic gamma delta T cells and exploits the potential of the cells to recognize and treat a broad range of cancers; and CTM-MSC, an injectable allogeneic umbilical cord derived mesenchymal stem cells for cartilage injury. It has research collaboration agreement with Sengkang General Hospital to provide CTM-MSC and its conditioned media for in vivo studies and Phase I clinical trial in Singapore. The company was incorporated in 2018 and is headquartered in Singapore.
Receive News & Ratings for Neurogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurogene and related companies with MarketBeat.com's FREE daily email newsletter.
